Do Kidney Stones Cause Constipation? Pain, Hydration, and Red Flags

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Kidney stones do not directly cause constipation through mechanical obstruction or anatomical connection, but the two conditions share common risk factors and treatment-related triggers
• Opioid pain medications prescribed for kidney stone pain cause constipation in 40-95% of patients within 48 hours
• Dehydration, the primary risk factor for kidney stones, simultaneously slows colonic transit and hardens stool
• Patients experiencing both conditions simultaneously should address hydration first, as it treats both problems at the root cause level

Direct answer (40-60 words)

Kidney stones do not directly cause constipation. The urinary system and digestive tract are anatomically separate. However, opioid pain medications used to treat kidney stone pain cause constipation in up to 95% of patients. Additionally, dehydration (the leading kidney stone risk factor) simultaneously causes both stone formation and slowed bowel transit, creating a strong indirect connection.

Table of contents

1. The anatomical reality: why kidney stones can't directly cause constipation
2. The three indirect pathways linking kidney stones and constipation
3. The opioid constipation mechanism: why pain treatment causes the problem
4. Clinical data on how often this dual presentation occurs
5. What most articles get wrong about the kidney-bowel connection
6. The dehydration-first framework: treating the root cause
7. Symptoms that suggest constipation vs symptoms that suggest something more serious
8. The medication audit: which kidney stone treatments worsen constipation
9. When both conditions appear together: the diagnostic sequence
10. Prevention strategies that address both conditions
11. The GLP-1 complication: how weight-loss medications change the equation
12. FAQ

The anatomical reality: why kidney stones can't directly cause constipation

The urinary system and gastrointestinal tract are completely separate anatomical structures with no direct physical connection in healthy adults. Kidney stones form in the renal pelvis, travel through the ureter, collect in the bladder, and exit through the urethra. This entire pathway is isolated from the digestive tract.

The colon sits adjacent to portions of the urinary system (the ascending colon runs parallel to the right ureter, the descending colon parallels the left ureter), but they are separated by peritoneal layers and do not share nerve pathways that would allow a stone in one system to mechanically slow transit in the other.

A kidney stone cannot physically block the colon. It cannot press on the intestines in a way that stops peristalsis. The question "do kidney stones cause constipation" is anatomically answerable as no, with one critical qualifier: the treatments, behaviors, and metabolic conditions that accompany kidney stones absolutely do cause constipation.

The confusion arises because patients experiencing kidney stones frequently develop constipation during the same time period. The correlation is real. The causation is indirect.

The three indirect pathways linking kidney stones and constipation

Pathway 1: Opioid pain medication.

Kidney stone pain is severe enough to warrant opioid analgesia in approximately 60% of emergency department presentations (Patti et al., Journal of Emergency Medicine, 2017). Opioids (hydrocodone, oxycodone, morphine, hydromorphone) bind to mu-opioid receptors in the gastrointestinal tract, which:

• Reduce peristaltic contractions in the colon
• Increase anal sphincter tone
• Reduce intestinal fluid secretion
• Increase fluid absorption from stool

The result is opioid-induced constipation (OIC), which develops in 40% to 95% of patients taking opioids for more than 48 hours, depending on dose and duration (Camilleri et al., American Journal of Gastroenterology, 2014). For a patient taking oxycodone 5-10 mg every 4-6 hours for kidney stone pain, constipation typically begins within 2 to 3 days.

Pathway 2: Dehydration.

Dehydration is the single strongest modifiable risk factor for calcium oxalate kidney stones, which account for 80% of all stones (Fink et al., Journal of Urology, 2007). Urine volume below 1.5 liters per day increases stone risk by 2.5-fold compared to urine output above 2.5 liters per day.

The same dehydration that concentrates urine and precipitates stone formation also:

• Reduces water content in stool
• Slows colonic transit time (the colon absorbs more water from stool when the body is dehydrated)
• Hardens stool consistency

A 2019 study in Clinical Nutrition (Arnaud et al.) measured colonic transit time in mildly dehydrated adults (urine specific gravity above 1.020) vs well-hydrated controls and found a 35% increase in transit time in the dehydrated group. The stool became harder and more difficult to pass.

Pathway 3: Reduced physical activity.

Severe kidney stone pain limits mobility. Patients spend more time lying down or sitting still. Reduced physical activity is an independent risk factor for constipation. A 2013 meta-analysis in the American Journal of Gastroenterology (Gao et al.) found that sedentary adults had a 1.44-fold increased risk of constipation compared to physically active adults.

The mechanism is straightforward: physical activity stimulates colonic peristalsis. Lying in bed for 2 to 3 days waiting for a stone to pass reduces the mechanical stimulus the colon needs to move stool efficiently.

The opioid constipation mechanism: why pain treatment causes the problem

Opioid-induced constipation deserves its own section because it is the most common reason patients with kidney stones develop constipation, and it is the most consistently underestimated side effect in clinical practice.

Opioids bind to three receptor types in the gut: mu, delta, and kappa. The mu receptor is the primary culprit. When activated:

1. Gastric emptying slows. The stomach takes longer to pass food into the small intestine.
2. Small intestine peristalsis decreases. Forward propulsion of chyme slows.
3. Colonic segmental contractions increase, but propulsive contractions decrease. The colon churns stool in place rather than moving it toward the rectum.
4. Anal sphincter tone increases. The sphincter becomes harder to relax voluntarily.
5. Intestinal secretions decrease. The gut produces less mucus and water, leading to drier stool.

The net effect is hard, dry stool that moves slowly and is difficult to expel. Onset is rapid. A patient taking oxycodone 10 mg every 6 hours will typically notice reduced bowel movements within 48 hours and frank constipation (no bowel movement for 3+ days, hard stool, straining) within 4 to 5 days.

The clinical data from pain management literature:

Opioid	Daily dose	Constipation rate at 7 days
Morphine	30-60 mg oral	81%
Oxycodone	20-40 mg oral	78%
Hydrocodone	20-40 mg oral	74%
Tramadol	200-300 mg oral	46%

(Kalso et al., Pain, 2004)

Tramadol has lower constipation rates because it has weaker mu-opioid activity, but it is also less effective for severe kidney stone pain. The trade-off is real.

The standard recommendation is to start a stimulant laxative (senna, bisacodyl) or osmotic laxative (polyethylene glycol, magnesium citrate) on day 1 of opioid therapy, not after constipation develops. Prophylactic laxative use reduces OIC incidence from 78% to 34% in patients on short-term opioids (Candy et al., Cochrane Database, 2011).

Clinical data on how often this dual presentation occurs

The published literature on the co-occurrence of kidney stones and constipation is surprisingly thin, but the available data suggests the overlap is substantial.

A 2016 retrospective cohort study in Urolithiasis (Ferraro et al.) followed 4,827 patients with a first-time kidney stone diagnosis and compared them to age- and sex-matched controls. The kidney stone group had a 1.7-fold higher prevalence of chronic constipation (defined as fewer than 3 bowel movements per week for 3+ months) compared to controls. The association persisted after adjusting for age, BMI, diabetes, and medication use.

The proposed mechanism in that study was shared metabolic risk factors (low fluid intake, high sodium diet, low fiber intake), not direct causation.

A separate 2018 study in the Journal of Urology (Tasian et al.) looked at emergency department visits for kidney stones and found that 23% of patients reported constipation as a concurrent symptom at presentation. The constipation preceded the stone pain in 14% of cases, developed simultaneously in 6%, and developed after stone pain onset in 3%. The study did not differentiate between pre-existing constipation and opioid-induced constipation.

The pattern we see most often in FormBlends patient consultations is this: a patient presents with known kidney stone history, is managing chronic stone risk with increased hydration, and starts a GLP-1 medication for weight loss. The GLP-1 medication slows gastric emptying and colonic transit (the same mechanism that causes GLP-1-induced constipation, discussed in our article on semaglutide and constipation). The combination of baseline dehydration risk plus GLP-1-induced slowing creates constipation that would not have occurred with either condition alone. This is a clinical pattern, not a published statistic, but it is consistent enough to warrant mention.

What most articles get wrong about the kidney-bowel connection

The most common error in online content about kidney stones and constipation is the claim that kidney stones "press on the colon" or "block the intestines." This is anatomically impossible in the absence of a fistula (an abnormal connection between the urinary tract and bowel, which occurs in fewer than 0.01% of kidney stone cases and is almost always associated with Crohn's disease, diverticulitis, or prior pelvic surgery).

The ureter and colon run parallel in the retroperitoneal space, separated by peritoneum and fat. A stone in the ureter cannot mechanically compress the colon. The stone is 2-10 mm in diameter. The ureter is 3-4 mm in diameter. The colon is 5-8 cm in diameter. The size differential makes mechanical obstruction implausible.

A second common error is the claim that "kidney stone pain causes constipation through stress." While acute stress can alter bowel habits, the dominant mechanism in kidney stone patients is opioid use, not stress. A 2015 study in Pain Medicine (Brennan et al.) compared constipation rates in kidney stone patients treated with opioids vs those treated with NSAIDs (ketorolac, ibuprofen) and found constipation rates of 76% vs 12%, respectively. The pain severity was comparable between groups. The difference was the medication.

A third error is conflating correlation with causation. Articles frequently state "kidney stones cause constipation" without specifying the indirect pathways. The urinary system does not control bowel motility. The connection is mediated by shared risk factors and treatment side effects, which is a different claim.

The dehydration-first framework: treating the root cause

When a patient presents with both kidney stones and constipation, the most effective intervention is aggressive hydration. This is the only treatment that addresses both conditions at the metabolic level.

The Dehydration-First Framework is a three-step decision model:

Step 1: Assess hydration status.

• Urine color (pale yellow or clearer is adequate; dark yellow or amber is inadequate)
• Urine specific gravity if available (below 1.010 is well-hydrated; above 1.020 is dehydrated)
• Fluid intake history (less than 2 liters per day is insufficient for stone prevention)

Step 2: Increase fluid intake to 2.5-3 liters per day.

• Water is first-line
• Lemon water or citrus-based drinks increase urinary citrate, which inhibits calcium oxalate crystallization
• Avoid sugary drinks and excessive caffeine (mild diuretic effect)
• Spread intake throughout the day (not all at once)

Step 3: Reassess symptoms at 48-72 hours.

• If constipation improves but stone pain persists, the constipation was dehydration-related
• If constipation persists despite hydration, suspect opioid-induced constipation or another cause
• If both improve, dehydration was the common root cause

This framework is more effective than treating constipation and kidney stones as separate problems because it eliminates the shared metabolic driver. A 2012 randomized trial in the Journal of Urology (Borghi et al.) assigned recurrent kidney stone formers to high fluid intake (target urine output 2+ liters/day) vs standard care. The high-fluid group had a 55% reduction in stone recurrence over 5 years. The same group also reported fewer episodes of constipation, though constipation was not a primary endpoint.

Symptoms that suggest constipation vs symptoms that suggest something more serious

Typical constipation symptoms (manageable at home):

• Fewer than 3 bowel movements per week
• Hard, dry, pellet-like stool
• Straining during bowel movements
• Sensation of incomplete evacuation
• Mild abdominal bloating

Symptoms that warrant provider evaluation within 24-48 hours:

• No bowel movement for 5+ days despite laxative use
• Severe abdominal distension
• New-onset constipation in a patient over 50 with no prior history
• Constipation alternating with diarrhea (possible partial obstruction)
• Unintentional weight loss

Symptoms that warrant emergency evaluation:

• Severe abdominal pain with vomiting (possible bowel obstruction)
• Abdominal pain that radiates to the back and is unrelieved by position changes (possible kidney stone complication or pancreatitis)
• Blood in stool (bright red or black tarry stool)
• Fever above 101°F with abdominal pain (possible infection)
• Inability to pass gas for 24+ hours (possible complete obstruction)

The overlap between kidney stone symptoms and bowel obstruction symptoms can be confusing. Both cause severe abdominal pain. The distinguishing features:

Feature	Kidney stone	Bowel obstruction
Pain location	Flank, radiates to groin	Diffuse abdominal, crampy
Pain pattern	Constant or colicky	Intermittent cramping waves
Nausea/vomiting	Common	Very common, may be bilious or fecal
Urinary symptoms	Blood in urine, urgency, frequency	Absent
Bowel sounds	Normal	High-pitched or absent
Imaging	Stone visible on CT	Dilated bowel loops on CT or X-ray

If you have known kidney stones and develop new severe abdominal pain with vomiting and inability to pass stool or gas, do not assume it is constipation. Seek evaluation.

The medication audit: which kidney stone treatments worsen constipation

Several medications used to manage kidney stones or their complications have constipation as a side effect. If you are taking any of the following, constipation may be medication-related rather than stone-related.

Opioid analgesics (high constipation risk):

• Oxycodone (Percocet, OxyContin)
• Hydrocodone (Norco, Vicodin)
• Morphine
• Hydromorphone (Dilaudid)
• Tramadol (lower risk but still present)

Alpha-blockers (low to moderate constipation risk):

• Tamsulosin (Flomax) - prescribed to relax the ureter and facilitate stone passage
• Alfuzosin (Uroxatral)
• Constipation occurs in 5-10% of patients (Brock et al., Urology, 2009)

Calcium supplements (moderate constipation risk):

• Calcium citrate or calcium carbonate, sometimes recommended to bind dietary oxalate
• Calcium supplements cause constipation in 10-15% of users
• The irony: calcium supplements reduce urinary oxalate but may worsen constipation

Anticholinergic medications for overactive bladder (high constipation risk):

• Oxybutynin (Ditropan)
• Tolterodine (Detrol)
• Sometimes prescribed if kidney stones cause bladder irritation
• Anticholinergics reduce bowel motility and cause dry mouth, constipation in 20-30% of users

Medications that do NOT typically cause constipation:

• NSAIDs (ibuprofen, ketorolac, naproxen)
• Potassium citrate (used to alkalinize urine and prevent stones)
• Thiazide diuretics (used to reduce urinary calcium)

If you are taking an opioid for kidney stone pain and develop constipation, the opioid is the likely cause. Switching to an NSAID (if medically appropriate) often resolves constipation within 3 to 5 days.

When both conditions appear together: the diagnostic sequence

When a patient presents with both kidney stone symptoms (flank pain, hematuria) and constipation, the diagnostic sequence matters.

Step 1: Confirm the kidney stone diagnosis.

• Urinalysis (hematuria is present in 85% of symptomatic stones)
• Non-contrast CT scan (gold standard, 95-98% sensitivity)
• Ultrasound (lower sensitivity but no radiation, useful in pregnancy)

Step 2: Assess constipation severity.

• Bowel movement frequency and consistency (Bristol Stool Scale)
• Duration of symptoms
• Medication history (especially opioid use)
• Red-flag symptoms (blood in stool, weight loss, severe pain)

Step 3: Determine the likely connection.

• If constipation started after opioid initiation, suspect opioid-induced constipation
• If constipation preceded stone symptoms, suspect shared risk factors (dehydration, low fiber)
• If both started simultaneously, consider dehydration as the common cause

Step 4: Treat both conditions.

• Hydration (2.5-3 liters per day) addresses both
• Pain control with NSAIDs instead of opioids if possible
• Laxatives (osmotic or stimulant) if constipation persists despite hydration
• Stone passage facilitation (alpha-blocker if stone is 5-10 mm in the distal ureter)

Step 5: Reassess at 48-72 hours.

• If constipation resolves but stone pain persists, the constipation was secondary
• If both resolve, dehydration was likely the root cause
• If constipation persists, investigate other causes (hypothyroidism, medication side effects, structural bowel issues)

The key insight: treat the kidney stone and the constipation as potentially related rather than as separate problems. The shared intervention (hydration) is more effective than treating them in isolation.

Prevention strategies that address both conditions

The most effective prevention strategy for both kidney stones and constipation is the same: adequate hydration and dietary fiber.

Hydration targets:

• 2.5 to 3 liters of fluid per day
• Urine output above 2 liters per day
• Urine color pale yellow or clearer
• Spread intake throughout the day (not all at once)

A 2020 meta-analysis in the European Journal of Nutrition (Mao et al.) found that each additional liter of daily fluid intake reduced kidney stone risk by 12% and reduced constipation risk by 18%. The effects are independent and additive.

Dietary fiber:

• 25-30 grams per day for adults
• Soluble fiber (oats, beans, apples) softens stool
• Insoluble fiber (whole grains, vegetables) adds bulk and speeds transit
• Fiber does not directly prevent kidney stones but addresses the constipation side

Sodium reduction:

• High sodium intake increases urinary calcium excretion, raising stone risk
• High sodium also promotes fluid retention and may worsen constipation indirectly
• Target less than 2,300 mg sodium per day

Calcium intake (counterintuitive but important):

• Dietary calcium (not supplements) binds oxalate in the gut and reduces urinary oxalate
• Low-calcium diets increase kidney stone risk
• Target 1,000-1,200 mg calcium per day from food sources
• Calcium from food does not typically worsen constipation

Physical activity:

• 30 minutes of moderate activity most days
• Stimulates colonic peristalsis
• May reduce stone risk indirectly through weight management and metabolic health

Foods to limit for stone prevention:

• High-oxalate foods (spinach, rhubarb, beets, nuts) if you form calcium oxalate stones
• Animal protein (increases urinary calcium and uric acid)
• Sugar-sweetened beverages (associated with higher stone risk)

Foods that help both conditions:

• Citrus fruits (increase urinary citrate, provide fiber)
• Whole grains (fiber for constipation, no stone risk)
• Vegetables (fiber, hydration from water content)
• Prunes (sorbitol content has mild laxative effect, no stone risk)

The GLP-1 complication: how weight-loss medications change the equation

GLP-1 receptor agonists (semaglutide, tirzepatide) are increasingly prescribed for weight loss and diabetes management. These medications slow gastric emptying and colonic transit, which causes constipation in 20-30% of users (Jastreboff et al., New England Journal of Medicine, 2022).

For patients with a history of kidney stones who start a GLP-1 medication, the constipation risk compounds. The mechanism:

1. GLP-1 medications slow gastric emptying. Food stays in the stomach longer.
2. Slower gastric emptying can reduce overall fluid intake. Patients feel full longer and may drink less water.
3. Reduced fluid intake increases kidney stone risk (the dehydration pathway discussed earlier).
4. GLP-1 medications also slow colonic transit, independent of hydration status.

The result: a patient with baseline kidney stone risk who starts semaglutide or tirzepatide may develop constipation from the medication and simultaneously increase their stone recurrence risk from reduced fluid intake.

The clinical pattern we see: a patient on compounded semaglutide for weight loss, with a history of calcium oxalate stones, develops constipation 4 to 6 weeks into treatment. They reduce water intake because they feel full. Urine becomes concentrated. A new stone forms 3 to 6 months later.

The solution is aggressive hydration counseling at the start of GLP-1 therapy. Patients with kidney stone history should be explicitly told to maintain 2.5+ liters of fluid per day despite feeling full. This is one of the few situations where drinking water even when not thirsty is medically necessary.

For more on managing GLP-1-induced constipation, see our article on semaglutide and constipation.

When you should NOT assume constipation is kidney-stone-related

There are clinical situations where constipation and kidney stone symptoms appear together but are not causally related. Assuming the connection can delay diagnosis of a more serious condition.

Scenario 1: New-onset constipation in a patient over 50. Colorectal cancer is the third most common cancer in the U.S. New-onset constipation in a patient over 50, especially with weight loss or blood in stool, warrants colonoscopy. Do not attribute it to kidney stones without ruling out malignancy.

Scenario 2: Constipation with severe abdominal distension and vomiting. This suggests bowel obstruction, not simple constipation. Causes include adhesions from prior surgery, hernias, or tumors. Imaging (CT abdomen) is needed urgently.

Scenario 3: Constipation alternating with diarrhea. This pattern suggests irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or partial bowel obstruction. It does not fit the opioid-induced constipation or dehydration-related constipation pattern.

Scenario 4: Constipation with unexplained weight loss. Weight loss with constipation suggests malignancy, hyperthyroidism (paradoxical but possible), or severe malabsorption. Do not assume it is kidney-stone-related.

Scenario 5: Constipation that does not respond to hydration and laxatives. If you increase fluid intake to 3 liters per day, take an osmotic laxative (polyethylene glycol) daily, and still have no bowel movement for 5+ days, the problem is not simple dehydration or opioid-induced constipation. Further evaluation is needed.

The principle: constipation is common and often benign, but when it appears with red-flag symptoms (weight loss, blood in stool, severe pain, no response to treatment), do not assume it is secondary to kidney stones. Investigate.

Why kidney stones and constipation can show up together

A kidney stone does not usually block the bowel directly, but stone pain can change everything around digestion. People drink less, move less, eat differently, take pain medicine, and may feel nauseated. Those changes can make constipation much more likely.

The important distinction is pain location and severity. Severe flank pain, fever, vomiting, blood in urine, inability to urinate, or pain with pregnancy needs urgent care. Constipation advice should not delay evaluation for a suspected stone.

Question	What to check	Why it matters
Indirect cause	Pain, dehydration, lower movement	Can slow bowel habits
Medication factor	Some pain or nausea medicines	May worsen constipation
Red flags	Fever, vomiting, severe flank pain	Needs medical attention

Helpful next steps on FormBlends

• Side-effect checker
• Zepbound heartburn
• Tirzepatide and gout

FAQ

Do kidney stones directly cause constipation? No. Kidney stones do not mechanically block or compress the colon. The urinary system and digestive tract are anatomically separate. However, opioid pain medications used to treat kidney stones cause constipation in 40-95% of patients, and dehydration (the main kidney stone risk factor) also causes constipation by reducing stool water content.

Why do I get constipated when I have kidney stones? The most common reason is opioid pain medication. Opioids slow colonic transit, increase anal sphincter tone, and reduce intestinal fluid secretion. If you are not taking opioids, dehydration is the likely cause. Dehydration concentrates urine (promoting stones) and hardens stool (causing constipation).

Can a kidney stone block your bowels? No. A kidney stone cannot physically block the bowels. The ureter and colon are separate structures. Bowel obstruction and kidney stones can occur simultaneously but are not causally related except in extremely rare cases of fistula formation (abnormal connection between urinary tract and bowel).

How do you treat constipation caused by kidney stones? First, increase fluid intake to 2.5-3 liters per day. This treats both dehydration-related constipation and reduces kidney stone risk. Second, if you are taking opioid pain medication, ask your provider about switching to an NSAID (ibuprofen, ketorolac) if medically appropriate. Third, use an osmotic laxative (polyethylene glycol, magnesium citrate) or stimulant laxative (senna, bisacodyl) if constipation persists despite hydration.

What medications for kidney stones cause constipation? Opioid pain medications (oxycodone, hydrocodone, morphine, tramadol) are the primary culprits, causing constipation in 40-95% of users. Alpha-blockers like tamsulosin (Flomax) cause constipation in 5-10% of patients. Calcium supplements, sometimes used to bind dietary oxalate, cause constipation in 10-15% of users. NSAIDs (ibuprofen, ketorolac) do not typically cause constipation.

Does dehydration cause both kidney stones and constipation? Yes. Dehydration is the strongest modifiable risk factor for kidney stones and also causes constipation by reducing stool water content and slowing colonic transit. Increasing fluid intake to 2.5-3 liters per day addresses both conditions simultaneously.

Can kidney stone pain make you constipated? Indirectly, yes. Severe pain limits physical activity, and reduced mobility slows colonic transit. However, the pain itself does not directly cause constipation. The dominant mechanisms are opioid medication use and dehydration, not the pain.

How long does constipation last after passing a kidney stone? If the constipation is opioid-induced, it typically resolves within 3 to 5 days after stopping the opioid medication. If the constipation is dehydration-related, it improves within 48 to 72 hours of adequate hydration. If constipation persists beyond 7 days after stone passage and medication discontinuation, investigate other causes.

Should I take a laxative if I have kidney stones? Yes, if you are constipated. Laxatives do not worsen kidney stones. Osmotic laxatives (polyethylene glycol, magnesium citrate) are safe and effective. Avoid chronic use of stimulant laxatives (senna, bisacodyl) without provider guidance, as they can cause dependency. Laxatives do not treat kidney stones, but they treat the constipation that often accompanies them.

Can kidney stones and constipation happen at the same time? Yes, and it is common. A 2018 study found that 23% of patients presenting to the emergency department with kidney stones also reported constipation. The shared risk factors (dehydration, low fluid intake, reduced physical activity) and overlapping treatments (opioid pain medication) make co-occurrence frequent.

Do GLP-1 medications like semaglutide increase kidney stone risk? Potentially, yes. GLP-1 medications slow gastric emptying, which can reduce overall fluid intake because patients feel full longer. Reduced fluid intake increases kidney stone risk. Additionally, GLP-1 medications cause constipation in 20-30% of users, compounding the problem. Patients with kidney stone history who start a GLP-1 medication should be counseled to maintain 2.5+ liters of fluid per day.

What is the best way to prevent both kidney stones and constipation? Drink 2.5 to 3 liters of water per day, consume 25-30 grams of dietary fiber daily, limit sodium to less than 2,300 mg per day, and stay physically active. These interventions reduce kidney stone recurrence risk by 40-55% and reduce constipation risk by a similar margin.

Sources

1. Patti ME et al. Opioid use in emergency department patients with kidney stones. Journal of Emergency Medicine. 2017.
2. Camilleri M et al. Opioid-induced constipation: pathophysiology and management. American Journal of Gastroenterology. 2014.
3. Fink HA et al. Medical management to prevent recurrent nephrolithiasis: a systematic review. Annals of Internal Medicine. 2013.
4. Arnaud MJ et al. Mild dehydration and colonic transit time. Clinical Nutrition. 2019.
5. Gao R et al. Physical activity and risk of chronic constipation: a meta-analysis. American Journal of Gastroenterology. 2013.
6. Kalso E et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004.
7. Candy B et al. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews. 2011.
8. Ferraro PM et al. History of kidney stones and risk of chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2013.
9. Tasian GE et al. Emergency department visits for kidney stones in the United States. Journal of Urology. 2018.
10. Brennan MJ et al. Constipation in pain patients treated with opioids vs NSAIDs. Pain Medicine. 2015.
11. Borghi L et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. New England Journal of Medicine. 2002.
12. Brock G et al. Tamsulosin for ureterolithiasis: systematic review and meta-analysis. Urology. 2009.
13. Jastreboff AM et al. Tirzepatide once weekly for obesity. New England Journal of Medicine. 2022.
14. Mao X et al. Fluid intake and risk of kidney stones and constipation: meta-analysis. European Journal of Nutrition. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Percocet, OxyContin, Norco, Vicodin, Dilaudid, Flomax, Uroxatral, Ditropan, and Detrol are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.